Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ZURA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
https://www.defenseworld.net
3 hours ago
businesswire.com
6 hours ago
https://thefly.com
6 hours ago
businesswire.com
6 hours ago
businesswire.com
8 hours ago
businesswire.com
16 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.18
vs -0.06
Q4.23
N/A
-0.19
vs NA
Q1.24
N/A
-0.02
vs -0.27
Q2.24
N/A
-0.17
vs -1.31
Q3.24
N/A
-0.26
vs -0.18
Q4.24
N/A
-0.08
vs -0.19
Q1.25
N/A
-0.19
vs -0.02
Q2.25
N/A
-0.17
vs -0.17
Q3.25
N/A
-0.18
vs -0.26
Q4.25
N/A
-0.18
vs -0.08
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
2K vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-34%
-0.34
vs NA
Q2.23
-49%
-0.49
vs -0.34
Q3.23
-13%
-0.13
vs -0.49
Q4.23
-14%
-0.14
vs -0.13
Q1.24
-1%
-0.01
vs -0.14
Q2.24
-8%
-0.08
vs -0.01
Q3.24
-14%
-0.14
vs -0.08
Q4.24
-9%
-0.09
vs -0.14
Q1.25
-13%
-0.13
vs -0.09
Q2.25
-13%
-0.13
vs -0.13
Institutionnal Ownership
QoQ
Q1.23
3
3
vs NA
NA
Q2.23
38
38
vs 3
1167%
Q3.23
41
41
vs 38
8%
Q4.23
44
44
vs 41
7%
Q1.24
44
44
vs 44
NA
Q2.24
56
56
vs 44
27%
Q3.24
84
84
vs 56
50%
Q4.24
93
93
vs 84
11%
Q1.25
75
75
vs 93
-19%
Q2.25
59
59
vs 75
-21%
Quote Panel
Key Metrics
Relative Strength
ZURA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
NASDAQ
Unprofitable
Unprofitable
1.34 ( 44.82%)
After-hours 4.32$
-0.01 (-0.23%)
Relative Strenght
93
Volume Buzz
3753%
Earning Acce
No
Dist 52w H.
15%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ZURA compares to sector?
ZURA
-6x
Forecast
2026-Revenue
-8%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Leerink Partners
initialisePrevious: Not converted
2024-11-04
Now: Outperform
H.C. Wainwright
initialisePrevious: Not converted
2024-09-05
Now: Neutral
Cantor Fitzgerald
initialisePrevious: Not converted
2024-06-12
Now: Overweight
Piper Sandler
initialisePrevious: Not converted
2024-05-03
Now: Overweight